Skip to main content

Table 3 Univariate and multivariate analysis for overall survival of major prognostic factors

From: External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer

Prognostic factor

Category

n

Median (months)

Univariate

Multivariate

    

Hazard ratio

95% CI

p value*

Hazard ratio

95% CI

p value**

Age (years)

70

43

17.0

1.00

0.35 - 1.03

0.062

   

>70

35

22.7

0.60

   

PSA at DTX initiation (ng/ml)

20

39

39.6

1.00

1.94 - 6.11

<0.001

1.00

 

0.058

>20

39

12.6

3.44

2.07

0.98 - 4.37

 

PSADT (months)

>2.4

38

31.4

1.00

1.48 - 4.41

0.001

1.00

 

0.033

2.4

40

16.7

2.56

1.88

1.05 - 3.36

 

ECOG performance status

1

68

20.3

1.00

1.55 - 6.26

0.001

1.00

 

0.740

2

10

4.1

3.11

1.16

0.49 - 2.74

 

Gleason score

7

21

31.2

1.00

0.89 - 3.00

0.113

   

>8

57

18.2

1.63

   

Armstrong risk classification

Good

51

30.1

1.00

  

1.00

 

0.060

Intermediate

17

14.2

2.48

1.32 - 4.66

<0.001

1.33

0.60 - 2.97

0.487

 

Poor

10

5.7

6.58

3.07 - 14.11

 

3.21

1.17 - 8.80

0.024

  1. Abbreviations: CI, confidence interval; PSA, prostate-specific antigen; PSADT, prostate-specific antigen doubling time; ECOG, Eastern Cooperative Oncology Group; ALP, alkaline phosphatase. *log rank test. **Cox proportional hazards model.